Page last updated: 2024-11-01

nimesulide and Carcinoma, Anaplastic

nimesulide has been researched along with Carcinoma, Anaplastic in 4 studies

nimesulide: structure
nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.

Research Excerpts

ExcerptRelevanceReference
"Cyclooxygenase-2 (COX-2) inhibitor nimesulide derivatives compounds A and B decreased aromatase activity in breast cancer cells via a novel mechanism different to aromatase inhibitors (AIs), and were defined as "aromatase suppressors"."7.76COX-2 inhibitor nimesulide analogs are aromatase suppressors in breast cancer cells. ( Cai, X; Chen, S; Hong, Y; Su, B, 2010)
"The chemopreventive potential of a selective cyclooxygenase-2 inhibitor, nimesulide (NIM), against the development of rat superficial urinary bladder carcinomas after initiation with N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) was examined."7.70Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. ( Akai, H; Denda, A; Kitayama, W; Konishi, Y; Okajima, E; Ozono, S; Sasaki, Y; Takahama, M; Wakabayashi, K, 1998)
"Cyclooxygenase-2 (COX-2) inhibitor nimesulide derivatives compounds A and B decreased aromatase activity in breast cancer cells via a novel mechanism different to aromatase inhibitors (AIs), and were defined as "aromatase suppressors"."3.76COX-2 inhibitor nimesulide analogs are aromatase suppressors in breast cancer cells. ( Cai, X; Chen, S; Hong, Y; Su, B, 2010)
"The chemopreventive potential of a selective cyclooxygenase-2 inhibitor, nimesulide (NIM), against the development of rat superficial urinary bladder carcinomas after initiation with N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) was examined."3.70Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. ( Akai, H; Denda, A; Kitayama, W; Konishi, Y; Okajima, E; Ozono, S; Sasaki, Y; Takahama, M; Wakabayashi, K, 1998)
"Diclofenac was COX-1/2 non-selective when tested in vitro, but a slightly preferential inhibitor of COX-2 when tested ex vivo."1.30Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. ( Giuliano, F; Warner, TD, 1999)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (50.00)18.2507
2000's1 (25.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Su, B1
Cai, X1
Hong, Y1
Chen, S1
Ng, AW1
Wong, FC1
Tung, SY1
Okajima, E1
Denda, A1
Ozono, S1
Takahama, M1
Akai, H1
Sasaki, Y1
Kitayama, W1
Wakabayashi, K1
Konishi, Y1
Giuliano, F1
Warner, TD1

Other Studies

4 other studies available for nimesulide and Carcinoma, Anaplastic

ArticleYear
COX-2 inhibitor nimesulide analogs are aromatase suppressors in breast cancer cells.
    The Journal of steroid biochemistry and molecular biology, 2010, Volume: 122, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Cell Lin

2010
Nimesulide--a new trigger of radiation recall reaction.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2007, Volume: 19, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Carcinoma; Humans; Male; Middle Aged; Nasopharyngeal Neopla

2007
Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine.
    Cancer research, 1998, Jul-15, Volume: 58, Issue:14

    Topics: Animals; Body Weight; Butylhydroxybutylnitrosamine; Carcinogens; Carcinoma; Cyclooxygenase Inhibitor

1998
Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs.
    British journal of pharmacology, 1999, Volume: 126, Issue:8

    Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Blood Pressu

1999